Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, COVID-19 immunisation, SARS-CoV-2 test, Vaccination failure
Clinical narrative: REVACCINATION WITH DIFFERENT COVID-19 VACCINE; CONFIRMED CLINICAL VACCINATION FAILURE; CONFIRMED COVID-19 INFECTION; This spontaneous report received from a consumer via other manufacturer (Pfizer Inc.) concerned a male of unspecified age, race and ethnicity. Initial information was processed along with the additional information received on 06-JUL-2023. The patient's height, and weight were not reported. The patient's concurrent conditions included: late stage 3 of copd, and 5th year of remission on one cancer, and other pre-existing medical conditions included: He has a lot of problems that has been going on for years. The patient was previously treated with covid-19 vaccine ad26. cov2. s (Dose number in series 1) (suspension for injection, route of admin were not reported batch number 213021A) dose was not reported, 1 total administered on 22-MAR-2021 for covid-19 prophylaxis.  It was unknown whether patient had any adverse events following vaccination with covid-19 vaccine ad26. cov2. s (Dose number in series 1) The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 2) (suspension for injection, route of admin, and batch number were not reported) dose was not reported, 1 total administered on NOV-2021 for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. On unspecified date in DEC-2022, the patient was sick (confirmed covid-19 infection) (Dose number in series 2). Patient received infusion treatment for covid on 06-DEC-2022. The patient received non-company suspect vaccine Moderna (Dose number in series 3) (elasomeran) (form of admin, route of admin, and batch number were not reported) dose was not reported, administered on 06-DEC-2022 for covid-19 prophylaxis which led to revaccination with different covid-19 vaccine (Dose number in series 3). Concomitant medications included dexamethasone, and doxycycline monohydrate.  On 27-JUN-2023, patient tested positive for being sick (Dose number in series 3). He called the doctor on 27-JUN-2023 (tuesday) because he knew he felt like he did when first got sick before. He called his primary physician right away. He did home test kits. He has 6 different manufactures of them. If test positive on one he would double check to make sure it is not a false positive and it was not (confirmed clinical vaccination failure) (Dose number in series 2) and received treatment medication paxlovid (tablet, oral, batch number: 674033 expiry: APR-2023) dose and frequency were not reported from 27-JUN-2023 for covid-19 treatment.  The action taken with covid-19 vaccine ad26.cov2.s, and elasomeran was not applicable. The outcome of the confirmed covid-19 infection, confirmed clinical vaccination failure and revaccination with different covid-19 vaccine was not reported. This report was serious (Other Medically Important Condition). This report was associated with product quality complaint 90000288748; Sender's Comments: V0: 20230702251-confirmed covid-19 infection. The event is deemed to be scientifically implausible, i.e., there is scientific evidence against a drug/event relationship; AND there is no known class effect. Therefore, this event is considered inconsistent with vaccine administration. 20230702251-confirmed clinical vaccination failure . The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event. Specifically: SPECIAL SITUATIONS. Therefore, this event is considered inconsistent with vaccine administration.